((自动化翻译由路透提供，请见免责声明 ))
9月25日 - ** Emergent BioSolutions 股价盘前上涨 12.6% 至 6.88 美元
** 该公司称已获得 (link) 2024年和2025年约4亿美元的疫苗、天花疫苗和水痘疫苗订单。
** EBS 称，这包括之前披露的美国政府采购疫苗的合同，价值超过 2.5 亿美元。
** 称 2024 年迄今为止，ACAM2000（其天花和麻痘疫苗）和 CNJ-016 （其疫苗病毒）已获得近 2.1 亿美元的客户订单。
** 在 2024 年剩余时间和 2025 年，公司确认将交付超过 1.85 亿美元的 ACAM2000 和 CNJ-016 订单。
** 截至上一交易日收盘，公司股价较年初翻了一番多
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.